#SciSparc #gains #competitive #advantage #additional #patent
This patent extends the protection and supplements six other previously issued US patents
TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company focused on the development of therapies to treat diseases of the central nervous system (the “Company” or “SciSparc”), announced today that it has filed U.S. patent and Trademark Office has granted him a new patent – US Patent No. 11,491,172 entitled: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS (the “Patent”).
This patent strengthens the company’s intellectual property portfolio and protects its core technologies in one of the world’s most important markets.
This is SciSparc’s seventh issued patent in the United States. Earlier, the company announced that it had received additional patents in Australia, Japan and Israel. The company’s IP portfolio currently includes nine patent families and two trademarks.
Around…
Read on GNW: SciSparc gains competitive advantage with additional US patent
